Selenium supplementation for Hashimoto's thyroiditis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  van Zuuren, Esther J ^a   Albusta, Amira Y ^b   Fedorowicz, Zbys ^c   Carter, Ben ^d   Pijl, Hanno ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMA INTERNATIONAL UNIVERSITY   (Bahrain)

^c Bahrain Branch   (Bahrain)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; LEVOTHYROXINE SODIUM; PLACEBO; SELENIUM; SELENOMETHIONINE; SODIUM SELENITE; THYROID PEROXIDASE ANTIBODY; THYROXINE;

ANTIBODY TITER; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; HASHIMOTO DISEASE; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH DISCOMFORT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WELLBEING; ADULT; DIET SUPPLEMENTATION;

ADULT; DIETARY SUPPLEMENTS; HASHIMOTO DISEASE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELENOMETHIONINE; SODIUM SELENITE; THYROXINE;

EID: 84883655868     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010223.pub2     Document Type: Review

References (57)

1. Karanikas G, Schuetz M, Kontur S, Duan H, Kommata S, Schoen R, et al.No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid 2008;18(1):7-12. [PUBMED: PMID: 18302514]
2. Krysiak R, Okopien B. The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto's thyroiditis. Journal of Clinical Endocrinology and Metabolism 2011;96(7):2206-15. [PUBMED: PMID: 21508145]
3. Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. Journal of Clinical Endocrinology and Metabolism 2007;92(4):1263-8. [PUBMED: PMID: 17284630]
4. Turker O, Kumanlioglu K, Karapolat I, Dogan I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. Journal of Endocrinology 2006;190(1):151-6. [PUBMED: PMID: 16837619]
5. Balázs C. The effect of selenium therapy on autoimmune thyroiditis [A szelénkezelés hatásaaz autoimmun thyreoiditisre (Hungarian)]. Orvosi Hetilap 2008;149(26):1227-32. [PUBMED: PMID: 18565817]
6. Contempré B, Duale NL, Dumont JE, Ngo B, Diplock AT, Vanderpas J. Effect of selenium supplementation on thyroid hormone metabolism in an iodine and selenium deficient population. Clinical Endocrinology 1992;36(6):579-83. [PUBMED: PMID: 1424183]
7. Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. European Journal of Endocrinology / European Federation of Endocrine Societies 2003;148(4):389-93. [PUBMED: PMID: 12656658]
8. Gartner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. Journal of Clinical Endocrinology and Metabolism 2002;87(4):1687-91. [PUBMED: PMID: 11932302]
9. Gartner R, Gasnier BC. Selenium in the treatment of autoimmune thyroiditis. Biofactors 2003;19(3-4):165-70. [PUBMED: PMID: 14757967]
10. Nacamulli D, Mian C, Petricca D, Lazzarotto F, Barollo S, Pozza D, et al.Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clinical Endocrinology (Oxf) 2010;73(4):535-9. [PUBMED: PMID: 20039895]
11. Krysiak R, Okopien B. Haemostatic effects of levothyroxine and selenomethionine in euthyroid patients with Hashimoto's thyroiditis. Thrombosis and Haemostasis 2012;108(5):973-80. [PUBMED: PMID: 22918596]
12. EudraCT2007-001107-38. Dose finding study to investigate efficacy and tolerability of a 6 month oral treatment with selenium in patients with autoimmune thyroiditis:prospective, controlled parallel group study with Cefasel versus placebo- double blind, randomised clinical multicentre study of phase II with four treatment groups. [Dosisfindungsstudie zur Untersuchung der Wirksamkeit und Vertraglichkeit einer 6-monatigen oralen Selen-Behandlung bei autoimmuner Thyreoiditis: prospektiver, kontrollierter Parallelvergleich von Cefasel versus Placebo- doppelblinde, randomisierte, klinische Multizenterstudie der Phase II mit vier Behandlungsgruppen]. www.clinicaltrialsregister.eu/ accessed 5 November 2012.
13. ISRCTN26633557. Selenium supplementation in euthyroid patients with thyroid peroxidase antibodies. http://www.controlled-trials.com/ISRCTN26633557 accessed 5 November 2012.
14. NCT01465867. Selenium supplementation in pregnancy (Serena). www.clinicaltrials.gov accessed 5 November 2012.
15. Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Archives of Internal Medicine 2008;168(4):404-10. [PUBMED: PMID: 18299496]
16. Brown KM, Arthur JR. Selenium, selenoproteins and human health: a review. Public Health Nutrition 2001;4(2B):593-9. [PUBMED: PMID: 11683552]
17. Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al.How to formulate research recommendations. British Medical Journal 2006;333(7572):804-6.
18. Bülow Pedersen I, Laurberg P, Knudsen N, Jørgensen T, Perrild H, Ovesen L, et al.A population study of the association between thyroid autoantibodies in serum and abnormalities in thyroid function and structure. Clinical Endocrinology 2005;62(6):713-20. [PUBMED: PMID: 15943834]
19. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Archives of Internal Medicine 2000;160(4):526-34. [PUBMED: PMID: 10695693]
20. Carta MG, Loviselli A, Hardoy MC, Massa S, Cadeddu M, Sardu C, et al.The link between thyroid autoimmunity (antithyroid peroxidase autoantibodies) with anxiety and mood disorders in the community: a field of interest for public health in the future. BMC Psychiatry 2004;18(4):25. [PUBMED: PMID: 15317653]
21. Chistiakov DA. Immunogenetics of Hashimoto's thyroiditis. Journal of Autoimmune Diseases 2005;2(1):1. [PUBMED: PMID: 15762980]
22. Dosiou C, Barnes J, Schwartz A, Negro R, Crapo L, Stagnaro-Green A. Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women. Journal of Clinical Endocrinology and Metabolism 2012;97(5):1536-46. [PUBMED: PMID: 22399510]
23. Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clincial Endocrinology 2013;78(2):155-64. [PUBMED: PMID:23046013]
24. Hashimoto thyroiditis. DynaMed [database online] EBSCO Publishing, 2013. http://search.ebscohost.com/login.aspx?direct=true&site=DynaMed&id=113943 Updated August 14, 2012. Accessed January 5, 2013.
25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [PUBMED: PMID: 9310563]
26. Fatourechi V, McConahey WM, Woolner LB. Hyperthyroidism associated with histologic Hashimoto's thyroiditis. Mayo Clinic Proceedings 1971;46(10):682-9. [PUBMED: PMID: 5171000]
27. Fink H, Hintze G. Autoimmune thyroiditis (Hashimoto's thyroiditis): current diagnostics and therapy [Die Autoimmunthyreoiditis (Hashimoto-Thyreoiditis): aktuelle Diagnostik und Therapie]. Medizinische Klinik 2010;105(7):485-93.
28. Goldhaber SB. Trace element risk assessment: essentiality vs. toxicity. Regulatory Toxicology and Pharmacology 2003;38(2):232-42. [PUBMED: PMID: 14550763]
29. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
30. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al.The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
31. Hu Y, McIntosh GH, Young GP. Selenium-rich foods: a promising approach to colorectal cancer prevention. Current Pharmaceutical Biotechnology 2012;13(1):165-72. [PUBMED: PMID: 21466436]
32. Huber G, Staub JJ, Meier C, Mitrache C, Guglielmetti M, Huber P, et al.Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. Journal of Clinical Endocrinology and Metabolism 2002;87(7):3221-6. [PUBMED: PMID: 12107228]
33. Hutfless S, Matos P, Talor MV, Caturegli P, Rose NR. Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease. Journal of Clinical Endocrinology and Metabolism 2011;96(9):E1466-71. [PUBMED: PMID:21715532]
34. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al.The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [DOI: 10.1136/bmj.c365]
35. Kraiem Z, Baron E, Kahana L, Sadeh O, Sheinfeld M. Changes in stimulating and blocking TSH receptor antibodies in a patient undergoing three cycles of transition from hypo to hyper-thyroidism and back to hypothyroidism. Clinical Endocrinology 1992;36(2):211-4. [PUBMED: PMID: 1637398]
36. Köhrle J, Jakob F, Contempré B, Dumont JE. Selenium, the thyroid, and the endocrine system. Endocrine Reviews 2005;26(7):944-84. [PUBMED: PMID: 16174820]
37. Lazarus JH, Hall R, Othman S, Parkes AB, Richards CJ, McCulloch B, et al.The clinical spectrum of postpartum thyroid disease. QJM 1996;89(6):429-35. [PUBMED: PMID: 8758046]
38. Li Y, Nishihara E, Kakudo K. Hashimoto's thyroiditis: old concepts and new insights. Current Opinion in Rheumatology 2011;23(1):102-7. [PUBMED: PMID: 21124092]
39. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al.The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine 2009;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]
40. Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, et al.Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in patients with Hashimoto's thyroiditis. Thyroid 2007;17(7):609-12.
41. Mitchell RN, Kumar V, Abbas AK, Fausto N. The endocrine system. In: Alpers CE, Anthony DC, Aster JC, Crawford JM, Crum CP, et al. editor(s). Robbins and Cotran Pathologic Basis of Disease. 8th Edition. Philadelphia, Pa: Elsevier, 2007:758-60.
42. Monsen ER. Dietary reference intakes for the antioxidant nutrients: vitamin C, vitamin E, selenium, and carotenoids. Journal of the American Dietetic Association 2000;100(6):637-40. [PUBMED: PMID: 10863565]
43. Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC, et al.Hashimoto's thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. Thyroid 2011;21(2):161-7. [PUBMED: PMID: 21186954]
44. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. New England Journal of Medicine 2003;348(26):2646-55. [PUBMED: PMID: 12826640]
45. Rayman MP. Food-chain selenium and human health: emphasis on intake. The British Journal of Nutrition 2008;100(2):254-68. [PUBMED: PMID: 18346308]
46. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
47. Saranac L, Zivanovic S, Bjelakovic B, Stamenkovic H, Novak M, Kamenov B. Why is the thyroid so prone to autoimmune disease?. Hormone Research in Paediatrics 2011;75(3):157-65. [PUBMED: PMID: 21346360]
48. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [PUBMED: PMID: 7823387]
49. Staii A, Mirocha S, Todorova-Koteva K, Glinberg S, Jaume JC. Hashimoto thyroiditis is more frequent than expected when diagnosed by cytology which uncovers a pre-clinical state. Thyroid Research 2010;3(1):11. [PUBMED: PMID: 21172028]
50. Stathatos N, Daniels GH. Autoimmune thyroid disease. Current Opinion in Rheumatology 2012;24(1):70-5. [PUBMED: PMID: 22157414]
51. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, et al.Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine 2007;147(4):217-23. [PUBMED: PMID: 17620655]
52. Stranges S, Laclaustra M, Ji C, Cappuccio FP, Navas-Acien A, Ordovas JM, et al.Higher selenium status is associated with adverse blood lipid profile in British adults. Journal of Nutrition 2010;140(1):81-7. [PUBMED: PMID: 19906812]
53. Stuart A. The changing scene in Hashimoto's disease: a review. Medical Hypotheses 2011;77:424-6. [PUBMED: PMID: 21741770]
54. Takasu N, Yamada T, Sato A, Nakagawa M, Komiya I, Nagasawa Y, et al.Graves' disease following hypothyroidism due to Hashimoto's disease: studies of eight cases. Clinical Endocrinology 1990;33(6):687-98. [PUBMED: PMID: 1982861]
55. Tomer Y. Genetic dissection of familial autoimmune thyroid diseases using whole genome screening. Autoimmunity Reviews 2002;1(4):198-204. [PUBMED: PMID: 12848996]
56. Toulis KA, Anastasilakis AD, Tzellos TG, Goulis DG, Kouvelas D. Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis. Thyroid 2010;20(10):1163-73. [PUBMED: PMID: 20883174]
57. Özen S, Berk Ö, Şimşek DG, Darcan S. Clinical course of Hashimoto's thyroiditis and effects of levothyroxine therapy on the clinical course of the disease in children and adolescents. Journal of Clinical Research in Pediatric Endocrinology 2011;3(4):192-7. [PUBMED: PMID: 22155461]